ArticlePLOS global public health2025
Status and prospects of seasonal malaria chemoprevention among children in Sahelian countries: A systematic review and meta-analysis.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In areas with seasonal malaria transmission, seasonal malaria chemoprevention (SMC) involves giving children a three-day course of sulfadoxine-pyrimethamine and amodiaquine once a month during the transmission season. This strategy has been used for ten years for children under five years of age. The logistical cost is affordable in malaria-endemic countries and varies slightly depending on accessibility. This systematic review and meta-analysis aims to better assess the effectiveness of seasonal malaria chemoprevention in reducing malaria incidence and prevalence in Sahelian countries, ten years after its introduction. This review followed the Preferred Reporting Items for Systematic Reviews (PRISMA) 2020 guidelines, and was based on Google scholar, MEDLINE (PubMed), the Cochrane library, African Journal Online, and Index Medicus African to compile its data. The combination of keywords such as "malaria", "Plasmodium", "malaria chemoprevention", "Sahel", "Efficacy", "Resistance", as well as Boolean operators (AND, OR) were used to inventory studies published between 2013 and 2023. Eligible studies included randomized clinical trials (RCTs), non-randomized trials, prospective cohort studies, intervention studies and observational studies. For randomized trials (RCTs), Cochrane's Risk of Bias 2 (RoB 2) tool was used to specifically assess the risk of bias in randomized controlled trials. And for non-randomized trials and observational studies, we applied the ROBINS-I (Risk of Bias in Non-randomized Studies of Interventions) tool, which included a meta-analysis of the studies. The study protocol was registered under the number (PROSPERO registry CRD42023413920), and R software was used for the meta-analysis. The meta-analysis shows that SMC is effective in reducing the incidence of uncomplicated malaria, severe malaria and mortality in children under five. Compared with control groups a reduction in the burden of malaria was observed in children receiving SMC. SMC appears to effectively reduce the incidence of malaria in children under five. However, it should be noted that SMC is always used alongside other prevention strategies, such as indoor residual spraying and long-lasting insecticide-treated nets. However, the epidemiological context of the Sahelian region is changing, and the strategy must be adapted to address the persistence of transmission during the dry season and the increase in malaria cases among older children.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.